Intravitreal treatment with vascular endothelial growth factor (VEGF) inhibitors (such as bevacizumab) has rapidly become an effective treatment for stopping choroidal neovascularization – often the most critical symptom of PXE [136–138]. The gene discussed is VEGFA; the disease is Pseudoxanthoma elasticum.